Publications scientifiques en 2022

Depuis le 15/03/2024

  1. Time to define common European criteria for therapeutic added value.
    Boucaud-Maitre D, Salvo F, Berdaï D.
    Therapie. 2022
  2. Spontaneous reporting of adverse-drug reactions as an outlet for patient dismay? The case of Levothyrox® change of excipients.
    Romani S, Fresse A, Parassol-Girard N, Gerard A, Levraut M, Yamani S, Van Obberghen E, Pariente A, Rocher F, Viard D, Drici MD.
    Fundam Clin Pharmacol. 2022
  3. Antihypertensive and lipid-lowering drugs usage after primary stroke in a large representative sample of the French population.
    Perrier J, Olié V, Gabet A, Tzourio C, Bezin J.
    Fundam Clin Pharmacol. 2022
  4. Antiherpetic drugs: a potential way to prevent Alzheimer's disease?
    Linard M, Bezin J, Hucteau E, Joly P, Garrigue I, Dartigues JF, Pariente A, Helmer C.
    Alzheimers Res Ther. 2022
  5. Prévention des risques liés à un usage inapproprié/consommation inutile des médicaments.
    Cracowski JL, Muller S, Anglade I, Bonnefond G, Bouhanick B, Bouquet S, Cabut S, Daynès P, Denis B, Durand D, Jonville-Béra AP, Lahouegue A, Léo M, Micallef J, Molimard M, Penfornis C, Querol-Ferrer V.
    Therapie. 2022
  6. Prevention of risks associated with inappropriate use/unnecessary consumption of medicines.
    Cracowski JL, Muller S, Anglade I, Bonnefond G, Bouhanick B, Bouquet S, Cabut S, Daynès P, Denis B, Durand D, Jonville-Béra AP, Lahouegue A, Léo M, Micallef J, Molimard M, Penfornis C, Querol-Ferrer V.
    Therapie. 2022
  7. Methoxpropamine (MXPr) in powder, urine and hair samples: Analytical characterization and metabolite identification of a new threat.
    Goncalves R, Castaing N, Richeval C, Ducint D, Titier K, Morvan E, Grélard A, Loquet A, Molimard M.
    Forensic Sci Int. 2022
  8. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).
    Greillier L, Gauvrit M, Paillaud E, Girard N, Montégut C, Boulahssass R, Wislez M, Pamoukdjian F, Corre R, Cabart M, Caillet P, Belaroussi Y, Frasca M, Noize P, Wang P, Mebarki S, Mathoulin-Pelissier S, Couderc AL.
    Cancers (Basel). 2022
  9. [Ketamine use in outpatients: What can we learn from current practices?]
    Salvati A, Daveluy A, Clavery R, Miremont-Salamé G, Micallef J, Frauger É; Réseau français d’addictovigilance.
    Therapie. 2022
  10. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273).
    Préta LH, Contejean A, Salvo F, Treluyer JM, Charlier C, Chouchana L.
    Br J Clin Pharmacol. 2022
  11. Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action.
    Raschi E, Salvo F, Khouri C.
    Br J Clin Pharmacol. 2022
  12. High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases.
    Volatier E, Salvo F, Pariente A, Courtois É, Escolano S, Tubert-Bitter P, Ahmed I.
    Drug Saf. 2022
  13. Psychoactive substance use among students: a cross-sectional analysis.
    Perino J, Tournier M, Mathieu C, Letinier L, Peyré A, Perret G, Peirera E, Fourrier-Réglat A, Pollet C, Fatseas M, Tzourio C, Daveluy A.
    Fundam Clin Pharmacol. 2022
  14. Emergency room admissions induced by drug-drug interactions in the elderly: a cross-sectional study.
    Letinier L, Pujade I, Duthoit P, Evrard G, Salvo F, Gil-Jardine C, Pariente A.
    Clin Transl Sci. 2022
  15. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).
    Duvignaud A, Lhomme E, Onaisi R, Sitta R, Gelley A, Chastang J, Piroth L, Binquet C, Dupouy J, Makinson A, Lefèvre B, Naccache JM, Roussillon C, Landman R, Wallet C, Karcher S, Journot V, Nguyen D, Pistone T, Bouchet S, Lafon ME, Molimard M, Thiébaut R, de Lamballerie X, Joseph JP, Richert L, Saint-Lary O, Djabarouti S, Wittkop L, Anglaret X, Malvy D; Coverage Study Group; SA1-1: Members of the COVERAGE France Study Group. Sponsor (CHU Bordeaux); National Trial Coordination Unit: CIC-EC 1401/EUCLID; MEREVA; National Coordinating Pharmacy; National Coordinating Laboratories; Bordeaux; Créteil; Bordeaux Study center; Investigating physicians; Coordination; Dijon Study center; Investigating physicians; Coordination; Nancy Study center: Investigating physicians; Coordination; Toulouse Study sites; Investigating physicians; Coordination; Bastia Study center; Investigating physicians; Coordination; Montpellier Study center: Investigating physicians; Coordination; Paris Study center 1: Collège National des Généralistes Enseignants (CNGE); Investigating physicians; Coordination; Paris Study center 2; Groupe Hospitalier Paris Saint Joseph (GHPSJ); Investigating physicians; Coordination; Paris Study center 3: Institut de Médecine et d’Epidémiologie Appliquée (IMEA); Coordination; Nantes/Angers Study center; Investigating physicians; Coordination; Others contributors; Scientific Advisory Board: Voting members; Non-voting members; Data Safety Monitoring Board.
    Clin Microbiol Infect. 2022
  16. Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study.
    Bénard-Laribière A, Hucteau E, Debette S, Kirchgesner J, Bezin J, Pariente A.
    BMJ. 2022
  17. Asthmatic bronchial smooth muscle increases rhinovirus replication within the bronchial epithelium.
    Esteves P, Allard B, Celle A, Dupin I, Maurat E, Ousova O, Thumerel M, Dupuy JW, Leste-Lasserre T, Marthan R, Girodet PO, Trian T, Berger P.
    Cell Rep. 2022
  18. The Multidimensional Nature of Research Ethics: Letters Issued by a French Research Ethics Committee Included Similar Proportions of Ethical and Scientific Queries.
    Haaser T, Bouteloup V, Berdaï D, Saux MC.
    J Empir Res Hum Res Ethics. 2022
  19. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring.
    Moulis G, Crickx E, Thomas L, Massy N, Mahévas M, Valnet-Rabier MB, Atzenhoffer M, Michel M, Godeau B, Bagheri H, Salvo F; and the French Covigilance COVID-19 Vaccine-ITP Study Group.
    Blood. 2022
  20. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study.
    Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Guen CG, Angoulvant F, Belot A; “French Covid-19 Paediatric Inflammation Consortium”£ and the “French Pharmacovigilance network”.
    Lancet Reg Health Eur. 2022
  21. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Martin GL, Jouganous J, Savidan R, Bellec A, Goehrs C, Benkebil M, Miremont G, Micallef J, Salvo F, Pariente A, Létinier L; French Network of Pharmacovigilance Centres.
    Drug Saf. 2022
  22. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
    Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A, Rigault A, Deschildre A, Molimard M.
    Eur Respir J. 2022
  23. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
    Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group.
    Therapie. 2022
  24. Myocardial infarction associated with erenumab: a case report.
    Perino J, Corand V, Laurent E, Théophile H, Miremont-Salamé G, Pariente A, Colas JL, Couffinhal T, Salvo F.
    Pharmacotherapy. 2022
  25. Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.
    Spini A, Rosellini P, Bellan C, Furiesi F, Giorgi S, Donnini S, Gini R, Ziche M, Salvo F, Roberto G.
    PLoS One. 2022
  26. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
    Rosellini P, Amintas S, Caumont C, Veillon R, Galland-Girodet S, Cuguillière A, Nguyen L, Domblides C, Gouverneur A, Merlio JP, Bezin J, Girodet PO.
    Eur J Cancer. 2022
  27. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49-64 and 65-70 years old.
    Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J.
    Pharmacoepidemiol Drug Saf. 2022
  28. Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use.
    Bertin C, Bezin J, Chenaf C, Delorme J, Kerckhove N, Pariente A, Tournier M, Authier N.
    Front Psychiatry. 2022
  29. Neuromodulation Treatments of Pathological Anxiety in Anxiety Disorders, Stressor-Related Disorders, and Major Depressive Disorder: A Dimensional Systematic Review and Meta-Analysis.
    Florian G, Singier A, Aouizerate B, Salvo F, Bienvenu TCM.
    Front Psychiatry. 2022
  30. [Hospitalizations after substance use during the COVID-19 pandemic]
    Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J.
    Therapie. 2022
  31. Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS/MS method in MRM3 mode.
    Villa A, Tremolet K, Martinez B, Petit M, Dascon X, Stanek J, Ducint D, Titier-Debeaupuis K, Verdun-Esquer C, Molimard M, Canal-Raffin M.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2022
  32. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
    Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, Cony-Makhoul P, Coiteux V, Sutton L, Abarah W, Pouaty C, Pignon JM, Choufi B, Visanica S, Deau B, Morisset L, Cayssials E, Molimard M, Bouchet S, Mahon FX, Nicolini F, Aegerter P, Cayuela JM, Delord M, Bruzzoni-Giovanelli H, Rousselot P; Groupe Français pour la LMC (Fi-LMC).
    Pharmaceutics. 2022
  33. Minors and young adult's hospitalizations after "chimique" consumption in Mayotte Island: Which substances are involved?
    Goncalves R, Peyré A, Castaing N, Beeken T, Olivier S, Combe P, Miremont-Salamé G, Titier K, Molimard M, Daveluy A.
    Therapie. 2022
  34. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
    Guyon J, Novion M, Fulda V, Ducint D, Molimard M, Couzi L, Kaminski H, Salvo F, Bouchet S.
    J Am Soc Mass Spectrom. 2022
  35. Benefit-risk balance of COVID drugs. New prospects.
    Cracowski JL, Richard V, Molimard M.
    Therapie. 2022
  36. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study.
    Mathieu C, Pambrun E, Bénard-Laribière A, Noize P, Faillie JL, Bezin J, Pariente A.
    Eur J Epidemiol. 2022
  37. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).
    Br J Haematol. 2022
  38. Second-degree burn induced by high-concentration topical capsaicin with mobility sequelae: a case report.
    Trin K, Perino J, Allouchery M, Géniaux H, Miremont G, Salvo F.
    Pain Pract. 2022
  39. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
    Gouverneur A, Avouac J, Prati C, Cracowski JL, Schaeverbeke T, Pariente A, Truchetet ME.
    Eur J Clin Pharmacol. 2022
  40. Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study.
    Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F.
    Br J Clin Pharmacol. 2022
  41. Transparency and robustness of safety signals.
    Khouri C, Fusaroli M, Salvo F, Raschi E.
    BMJ. 2022
  42. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
    Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL.
    Diabetes Care. 2022
  43. Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis.
    Spini A, Ciccone V, Rosellini P, Ziche M, Lucenteforte E, Salvo F, Donnini S.
    Cancers (Basel). 2022
  44. Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study.
    Sanchez-Pena P, Milpied B, Darrigade AS, Miremont-Salamé G, Pariente A, Beylot Barry M.
    Ann Dermatol Venereol. 2022
  45. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
    Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F.
    Psychopharmacology (Berl). 2022
  46. Systematic review on sex differences for drug use after stroke.
    Perrier J, Renard M, Pariente A, Bezin J.
    Therapie. 2022
  47. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
    Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
    Therapie. 2022
  48. Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
    Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
    Therapie. 2022
  49. Trends in use of benzodiazepines and Z-drugs in France from 2012 to 2020.
    Bénard-Laribière A, Pambrun E, Diop PY, Pariente A.
    Therapie. 2022